Roche Gains FDA Nod on Combo Therapy for Aggressive Lung Cancer

Roche Holding AG secured US approval for a drug combination maintenance therapy to treat one of the most aggressive forms of lung cancer.

The Swiss drugmaker’s Tecentriq cancer drug with Jazz Pharmaceuticals Plc’s lurbinectedin was cleared by the US Food and Drug Administration to treat patients with extensive-stage small cell lung cancer, which is known as ES-SCLC.